UNSPSC 51433604: Perhexiline

This classification denotes a calcium channel blocker, cardiovascular agent, and vasodilator agent with the molecular formula C19H35N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KU65374X44, chemically known as 2-(2,2-dicyclohexylethyl)piperidine but generally known as perhexiline, which bears US NIH Compound Identifier 4746. European Medicines Agency schedules Perhexiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09726MIG.

UNSPSC 51433604 Perhexiline is a Commodity code that in practice covers state and local procurement of prescription pharmaceuticals and injectable medications for emergency medical services, public health programs, and cooperative pharmacy benefit initiatives. Recent solicitations show state and local governments buying advanced life support medications (epinephrine, adenosine, labetalol, diltiazem), generic multi-source pharmaceuticals distributed through authorized wholesalers, and direct-to-manufacturer prescription fulfillment programs. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances administering pharmaceutical contracts for participating state and local members across multiple jurisdictions. The City of Tampa's fire department and the Texas Health and Human Services Commission represent the range of end-users, while Minnesota's MMCAP demonstrates the scale of cooperative purchasing vehicles that aggregate demand across state and local government facilities.

Activity under this code spans multiple states and procurement types. The City of Tampa issued an IFB (Solicitation 26P00188) for advanced life support medications with a response deadline of April 8, 2026, and an estimated contract value of $40,000, requiring vendors to supply specific medication line items with nine-month minimum expiration dates and firm pricing including freight to Tampa, Florida; the contract carries a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount not to exceed $10,000. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) closing March 26, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across Minnesota, Oregon, and other participating jurisdictions through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with evaluation weighted 75 percent on price competitiveness and contract terms effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) with an April 3, 2026 response deadline to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer program designed to inform future formal procurement strategy. Recent activity shows concentration in Texas, Minnesota, and Florida, with cooperative purchasing mechanisms extending reach across multiple states and local government members.